Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to characterize the pharmacokinetics of TV-45070 in plasma following single and multiple-dose topical application of 8% TV-45070 ointment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TV-45070 7% | Experimental | twice daily topical application to 7% body surface area for 7.5 days (15 applications) |
|
| TV-45070 21% | Experimental | twice daily topical application to 21% body surface area for 7.5 days (15 applications) |
|
| TV-45070 53% | Experimental | twice daily topical application to 53% body surface area for 7.5 days (15 applications) |
|
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| TV-45070 | Drug | TV-45070 8% ointment |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Plasma concentrations | Day 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Drug level in skin | Days 1, 8, 15, 22, 29 | |
| Excretion of drug in urine | Day 8 | |
| Identification of metabolites in blood |
Not provided
Inclusion Criteria:
Exclusion Criteria:
History or evidence of clinically significant illness or surgery
Presence of open wounds, sunburn, tattoo, major scarring, non-intact or damaged in the proposed application area that would interfere with the application of the study drug treatments or biopsies.
History of significant drug or alcohol abuse
Use of prescription drugs within 30 days or 5 half-lives (whichever is longer) prior to Day 1.
Use of topical application of an OTC medicated or prescription medication or other skin creams/ointments (eg, moisturizers, balms) in the areas intended for study drug administration within 7 days prior to Day 1. Use of topical capsaicin within 6 months prior to Day 1.
Pregnant or nursing females
Shaving or waxing the planned study treatment application area within 7 days prior Day 1.
Laser hair removal of the planned study treatment application area within 2 months prior to Day 1.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Teva Medical Expert, MD | Teva Branded Pharmaceutical Products R&D, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Teva Investigational Site 12961 | Lenexa | Kansas | United States |
Not provided
| ID | Term |
|---|---|
| C000625639 | TV-45070 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Placebo |
|
| Days 8, 10 |
| Identification of metabolites in urine | Day 8 |
| Identification of metabolites in skin | Days 1, 8, 15, 22, 29 |
| Intraepidermal nerve fiber density in skin | Days 1, 8, 15, 29 |
| Percentage of Participants with Adverse Events | 10 Weeks |